…
NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
NetraMark Holdings Inc., quoted on the OTC Pink under ticker AINMF, has limited public information and no verifiable description of its core operations. Long-term growth drivers are unclear and would depend on future audited financials or material business developments. Investors may view the company as a speculative opportunity if management demonstrates credible revenue growth or strategic transactions, though such outcomes remain uncertain.
Material investment risks include very low trading liquidity, potential for significant share dilution, absence of audited financials and limited corporate governance, plus heightened regulatory and financing uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -5.22M | -3.33M | -14.17M | -13.70M | -5.08M |
| Net income | -5.22M | -3.33M | -14.17M | -13.45M | -5.08M |
| Selling general administrative | 5.70M | 3.93M | 5.45M | 7.45M | 5.05M |
| Reconciled depreciation | - | 0.00M | 0.61M | 0.60M | - |
| Ebit | - | - | - | -7.40M | -5.05M |
| Ebitda | - | - | - | -7.34M | -5.05M |
| Operating income | -5.22M | -3.33M | -5.86M | -7.93M | -5.05M |
| Tax provision | - | - | 0.00M | -0.25M | - |
| Income tax expense | - | - | - | -0.25M | - |
| Total revenue | 0.43M | 0.46M | 0.09M | 0.11M | 0.00M |
| Total operating expenses | 5.65M | 3.79M | 5.95M | 8.05M | 5.05M |
| Total other income expense net | 0.04M | 0.14M | -8.31M | -5.76M | -0.04M |
| Net income from continuing ops | -5.22M | -3.33M | -14.17M | -13.45M | -5.08M |
| Net income applicable to common shares | - | - | - | -13.45M | -5.08M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 2.18M | 0.21M | 1.91M | 9.20M | 8.40M |
| Intangible assets | - | - | - | 2.52M | 1.58M |
| Total liab | 0.34M | 0.41M | 0.82M | 1.09M | 0.46M |
| Total stockholder equity | 1.83M | -0.20M | 1.09M | 8.11M | 7.94M |
| Deferred long term liab | - | - | - | - | 1.58M |
| Other current liab | - | - | - | 0.02M | - |
| Common stock | - | - | - | 24.25M | 11.75M |
| Capital stock | 39.02M | 30.50M | 28.82M | 24.25M | 11.75M |
| Retained earnings | -41.55M | -36.33M | -32.99M | -18.82M | -5.38M |
| Good will | - | - | 0.00M | 6.41M | - |
| Other assets | - | - | - | - | 1.58M |
| Cash | 1.50M | 0.06M | 1.78M | 0.01M | 6.29M |
| Total current liabilities | 0.34M | 0.41M | 0.82M | 1.09M | 0.46M |
| Total current assets | 2.18M | 0.21M | 1.91M | 0.28M | 6.82M |
| Net tangible assets | - | - | - | -0.81M | 7.94M |
| Short term investments | 0.53M | 0.01M | 0.01M | 0.01M | 0.04M |
| Net receivables | 0.00M | 0.08M | 0.00M | 0.25M | 0.35M |
| Accounts payable | - | - | - | 1.06M | 0.46M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 8.92M | 1.58M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | -0.51M | -0.00M | 0.00M | 0.04M | -0.04M |
| Change to liabilities | - | - | - | 0.47M | 0.32M |
| Total cashflows from investing activities | - | - | - | -2.19M | -1.62M |
| Total cash from financing activities | 5.76M | 0.57M | 4.16M | 0.69M | 8.67M |
| Change to operating activities | - | - | - | 0.24M | -0.37M |
| Net income | -5.22M | -3.33M | -14.17M | -13.45M | -5.08M |
| Change in cash | 1.44M | -1.72M | 1.77M | -6.28M | 4.44M |
| Begin period cash flow | 0.06M | 1.78M | 0.01M | 6.29M | 1.84M |
| End period cash flow | 1.50M | 0.06M | 1.78M | 0.01M | 6.29M |
| Total cash from operating activities | -3.81M | -2.29M | -2.39M | -4.78M | -2.60M |
| Issuance of capital stock | - | 0.00M | 3.97M | 0.58M | 8.67M |
| Depreciation | - | 0.00M | 0.61M | 0.60M | 0.60M |
| Change to account receivables | 0.08M | -0.08M | 0.01M | -0.01M | -0.01M |
| Change to netincome | - | - | - | 7.37M | 2.53M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.15M | 0.00M |
| Change in working capital | -0.07M | -0.43M | 0.23M | 0.70M | -1.67M |
| Stock based compensation | 0.82M | 0.60M | 1.43M | 1.25M | 1.21M |
| Other non cash items | 0.66M | 0.88M | 1.31M | 0.61M | 1.32M |
| Free cash flow | -3.81M | -2.29M | -2.39M | -4.93M | -4.23M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AINMF NetraMark Holdings Inc. |
- -% |
0.35 | - | - | 62.23 | 17.52 | 97.83 | -3.60 |
| VEEV Veeva Systems Inc Class A |
-0.05 0.02% |
266.22 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
-6.60 5.03% |
124.50 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-5.60 9.39% |
54.01 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.07 1.31% |
5.28 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. George Achilleos | President, CEO & Director | NA |
| Dr. Joseph Geraci Ph.D. | Founder, Chief Scientific & Technical Officer and Director | NA |
| Mr. Swapan Kakumanu ACA, ACWA, CGA | CFO & Corporate Secretary | 1970 |
| Mr. Josh Spiegel | President of NetraMark Corp | NA |
| Ms. Jaime Hackett | Vice President of Marketing | NA |
| Dr. Luca Pani M.D. | Chief Innovation & Regulatory Officer and Chief Medical Advisor | NA |
| Dr. Kaveh Kavoosi | Head of Progressive Medicine | NA |
| Dr. Larry Alphs | Chief Medical Officer & Member of Advisory Board | NA |
| Dr. Angelico Carta M.D. | Chief Strategy Officer | NA |
| Dr. Jan Sedway Ph.D. | Senior Vice President of Clinical Science | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.